Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference

PURCHASE, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), announced that the Company’s president and CEO, Lisa Ricciardi intends to participate in the 2026 Jefferies Global Healthcare Conference taking place November 16-19 in London, UK. The meeting is Europe’s largest healthcare-dedicated financial conference, attracting an estimated 800 global public and private companies across the life sciences. During the meeting, Ms. Ricciardi will discuss the company’s recent FDA meeting to finalize the selection of endpoints for the planned Phase 3 study of zervimesine in dementia with Lewy bodies (DLB). She will be available for one-on-one investor meetings throughout the conference and investors interested in arranging meetings should contact their Jefferies representative.